Abstract
The dopaminergic prodrug dibenzoyl-6,7-ADTN (DB-6,7-ADTN) can enter the brain following intraperitoneal injection and be hydrolysed to produce low concentrations of the dopamine agonist 6,7-ADTN. Intraperitoneal injections of DB-6,7-ADTN produce a decrease in motor activity and in the present study this response has been characterised, and the underlying mechanisms examined. Doses of 10-100 mumol/kg DB-6,7-ADTN elicit a strong hypomotive response, which is dose dependent. Treated animals are significantly less active than controls. DB-6,7-ADTN hypomotility was significantly attenuated by the non-sedative dopamine receptor antagonist sulpiride (62 mumol/kg, i.p.), but haloperidol (0.3 mumol/kg, i.p.) and cis-flupenthixol (0.45 mumol/kg, i.p.) were without effect. The hypomotility due to DB-6,7-ADTN was also antagonised by yohimbine (13 mumol/kg, i.p.) and piperoxane (21 mumol/kg i.p.), drugs which act mainly by blocking presynaptic (alpha 2) adrenergic receptors. Prazosin (1.5 mumol/kg, i.p.), drugs which act mainly by blocking presynaptic (alpha 2) adrenergic receptors. Prazosin (1.5 mumol/kg, i.p.), a postsynaptic (alpha 1) adrenergic blocker, did not affect the hypomotility, and nor did a range of other neurotransmitter antag...Continue Reading
References
Jan 14, 1976·Naunyn-Schmiedeberg's Archives of Pharmacology·N E AndénU Strömbom
Jul 1, 1976·The Journal of Pharmacy and Pharmacology·S R SniderS Fahn
May 1, 1977·British Journal of Pharmacology·J C DoxeyJ M Walker
Jul 1, 1977·The Journal of Pharmacy and Pharmacology·G N WoodruffJ D McDermed
Aug 1, 1978·Journal of Medicinal Chemistry·A S HornA H Mulder
Jul 1, 1979·The Journal of Pharmacy and Pharmacology·P E Hicks, J G Cannon
Jun 18, 1979·Naunyn-Schmiedeberg's Archives of Pharmacology·A Delini-StulaO Büch
Dec 1, 1975·European Journal of Pharmacology·K StarkeT Endo
Mar 1, 1979·British Journal of Pharmacology·D A Brown, M P Caulfield
Oct 5, 1979·Science·L R SkirbollB S Bunney
Nov 23, 1979·European Journal of Pharmacology·A S HornD Dijkstra
Nov 23, 1978·Nature·A S HornA Westerbrink
Feb 18, 1977·Science·S M Antelman, A R Caggiula
Jun 1, 1976·European Journal of Pharmacology·B H Westerink, J Korf
Aug 1, 1976·Neuropharmacology·R J Borgman
Dec 9, 1976·Nature·G Di ChiaraG L Gessa
Aug 1, 1975·European Journal of Pharmacology·R Papeschi, P Theiss
Jan 1, 1975·Journal of Neural Transmission·U Strömbom
Nov 1, 1972·Animal Behaviour·S E File, S Day
Dec 1, 1969·International Journal of Neuropharmacology·L R Grunden
Jan 1, 1970·European Journal of Pharmacology·T Persson, B Waldeck
Feb 1, 1980·Naunyn-Schmiedeberg's Archives of Pharmacology·Y NomuraT Segawa
Oct 3, 1980·European Journal of Pharmacology·A H MulderA S Horn
Jan 11, 1980·European Journal of Pharmacology·B H WesterinkE Wirix
Jun 27, 1980·European Journal of Pharmacology·H RollemaA S Horn
Jun 1, 1980·Naunyn-Schmiedeberg's Archives of Pharmacology·T AlanderM Grabowska-Andén
Oct 6, 1980·Brain Research·P Weinreich, P Seeman
Citations
Sep 10, 1982·European Journal of Pharmacology·A S HornA H Mulder
Jun 16, 1982·European Journal of Pharmacology·J C van OeneA S Horn
Aug 5, 1983·European Journal of Pharmacology·E J Hartley, P Seeman
May 20, 1983·European Journal of Pharmacology·J Arnt
Jul 13, 1984·European Journal of Pharmacology·G Zetler
Nov 13, 1984·European Journal of Pharmacology·H HörtnaglW Kobinger
Feb 26, 1985·European Journal of Pharmacology·B HazelhoffA S Horn
Jun 17, 1986·European Journal of Pharmacology·J Van der WeideA S Horn
Mar 1, 1988·European Journal of Pharmacology·J Van der WeideA S Horn
Jan 1, 1982·Pharmacology, Biochemistry, and Behavior·H Y Meltzer
Sep 1, 1986·Neuropharmacology·M ElamT H Svensson
Dec 1, 1981·Neuropharmacology·C SumnersA S Horn
Jan 1, 1985·Journal of Neural Transmission·D ClarkA Carlsson
Sep 1, 1988·Pharmacological Research Communications·F FerrariA Tampieri